Evidence map›Paper›PMID 35665462›Full record

ArticleJournal of neuro-oncology2022

Significant survival improvements for patients with melanoma brain metastases: can we reach cure in the current era?

Assaf Berger, Kenneth Bernstein, Juan Diego Alzate, Reed Mullen, Joshua S Silverman, Erik P Sulman, Bernadine R Donahue, Anna C Pavlick, Jason Gurewitz, Monica Mureb and 6 more

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of neuro-oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 3 institutions in 1 country.

Assaf BergerDepartment of Neurological Surgery, Center for Advanced Radiosurgery, NYU Langone Health Medical Center, New York University, 530 First Avenue, New York, NY, 10016, USA. assaf.berger@gmail.com.
Kenneth BernsteinDepartment of Neurological Surgery, Center for Advanced Radiosurgery, NYU Langone Health Medical Center, New York University, 530 First Avenue, New York, NY, 10016, USA.
Juan Diego AlzateDepartment of Neurological Surgery, Center for Advanced Radiosurgery, NYU Langone Health Medical Center, New York University, 530 First Avenue, New York, NY, 10016, USA.
Reed MullenDepartment of Neurological Surgery, Center for Advanced Radiosurgery, NYU Langone Health Medical Center, New York University, 530 First Avenue, New York, NY, 10016, USA.
Joshua S SilvermanDepartment of Radiation Oncology, NYU Langone Health Medical Center, New York University, New York, USA.
Erik P SulmanDepartment of Radiation Oncology, NYU Langone Health Medical Center, New York University, New York, USA.
Bernadine R DonahueDepartment of Radiation Oncology, NYU Langone Health Medical Center, New York University, New York, USA.
Anna C PavlickMedical Oncology, Perlmutter Cancer Center, NYU Langone Health Medical Center, New York University, New York, USA.
Jason GurewitzMedical Oncology, Perlmutter Cancer Center, NYU Langone Health Medical Center, New York University, New York, USA.
Monica MurebDepartment of Neurosurgery, Westchester Medical Center, Valhalla, USA.
Janice MehnertMedical Oncology, Perlmutter Cancer Center, NYU Langone Health Medical Center, New York University, New York, USA.
Kathleen MaddenMedical Oncology, Perlmutter Cancer Center, NYU Langone Health Medical Center, New York University, New York, USA.
Amy PalermoDepartment of Neurological Surgery, Center for Advanced Radiosurgery, NYU Langone Health Medical Center, New York University, 530 First Avenue, New York, NY, 10016, USA.
Jeffrey S WeberMedical Oncology, Perlmutter Cancer Center, NYU Langone Health Medical Center, New York University, New York, USA.
John G GolfinosDepartment of Neurological Surgery, Center for Advanced Radiosurgery, NYU Langone Health Medical Center, New York University, 530 First Avenue, New York, NY, 10016, USA.
Douglas KondziolkaDepartment of Neurological Surgery, Center for Advanced Radiosurgery, NYU Langone Health Medical Center, New York University, 530 First Avenue, New York, NY, 10016, USA.
NYU Langone Health · USNeurological Surgery · USWestchester Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeNew therapies for melanoma have been associated with increasing survival expectations, as opposed to the dismal outcomes of only a decade ago. Using a prospective registry, we aimed to define current survival goals for melanoma patients with brain metastases (BM), based on state-of-the-art multimodality care.

methodsWe reviewed 171 melanoma patients with BM receiving stereotactic radiosurgery (SRS) who were followed with point-of-care data collection between 2012 and 2020. Clinical, molecular and imaging data were collected, including systemic treatment and radiosurgical parameters.

resultsMean age was 63 ± 15 years, 39% were female and 29% had BRAF-mutated tumors. Median overall survival after radiosurgery was 15.7 months (95% Confidence Interval 11.4-27.7) and 25 months in patients managed since 2015. Thirty-two patients survived [Formula: see text] 5 years from their initial SRS. BRAF mutation-targeted therapies showed a survival advantage in comparison to chemotherapy (p = 0.009), but not to immunotherapy (p = 0.09). In a multivariable analysis, both immunotherapy and the number of metastases at 1

conclusionLong-term survival in patients with melanoma BM is achievable in the current era of SRS combined with immunotherapies. For those alive [Formula: see text] 5 years after first SRS, 16% had been also off systemic or local brain therapy for over 5 years. Given late recurrences of melanoma, caution is warranted, however prolonged survival off active treatment in a subset of our patients raises the potential for cure.

Indexed as

Brain NeoplasmsMelanomaRadiosurgeryAgedFemaleHumansImmunotherapyMaleMiddle AgedMolecular Targeted TherapyRetrospective StudiesBRAFBrain metastasesImmunotherapyMelanomaStereotactic radiosurgery

Identifiers

PMID35665462
OpenAlexW4281869980

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.